Search

Hutchison China MediTech Ltd ADR

Abrir

SetorSaúde

10.76 -5.03

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.76

Máximo

11.55

Indicadores-chave

By Trading Economics

Rendimento

978K

Vendas

135M

P/E

Médio do Setor

4.196

64.641

Margem de lucro

0.722

Funcionários

1,796

EBITDA

-14M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+30.55% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.9B

Abertura anterior

15.79

Fecho anterior

10.76

Sentimento de Notícias

By Acuity

100%

0%

322 / 340 Ranking em Healthcare

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de jul. de 2026, 23:56 UTC

News

Industrial Logistics Properties Trust shares declined after second-quarter results missed expectations, reporting a loss of -$0.22 per share and revenue of $114.12 million.

29 de jul. de 2026, 23:56 UTC

News

Adobe shares rose after-market, reaching about $263.62. Elevated options volume and a lower put/call ratio reflect bullish sentiment.

29 de jul. de 2026, 23:56 UTC

News

Logitech International SA's quarterly report filing has led to shares trading higher in after-market hours, reflecting increased investor interest.

29 de jul. de 2026, 23:52 UTC

Social Media
News

Robinhood Markets reported record Q2 revenue of $1.31 billion but shares are lower in after-market trading due to a drop in cryptocurrency revenue and revised expense outlook.

29 de jul. de 2026, 23:51 UTC

Social Media
Correlated Moves
News

Hecla Mining reported positive Q2 exploration results, extending high-grade mineralization at Keno Hill and Midas. Shares are higher in after-market trading.

29 de jul. de 2026, 23:51 UTC

Social Media
News

PennyMac Mortgage Investment Trust's Q2 EPS of $0.23 missed estimates, with revenue at $73 million. Shares are trading lower in after-market hours.

29 de jul. de 2026, 23:51 UTC

News

Five9 Inc will join the S&P SmallCap 600 index, effective August 3, 2026. Shares are higher in after-market trading following the announcement.

29 de jul. de 2026, 23:51 UTC

News

General Motors Co shares declined in after-market hours as Ford's strong earnings and guidance overshadowed its outlook amid broader market pressures.

29 de jul. de 2026, 23:51 UTC

Social Media
News

American Water Works reported strong Q2 earnings and revenue but shares declined slightly in after-market hours, reflecting broader market trends.

29 de jul. de 2026, 23:46 UTC

Social Media
News

DoorDash Inc launches DoorDash Air, a new drone delivery unit. Shares are higher in after-market trading, continuing recent upward momentum.

29 de jul. de 2026, 23:46 UTC

News

Avis Budget Group reported second-quarter earnings below expectations, with revenue at $3 billion and EPS of $0.98. Shares are lower in after-market hours.

29 de jul. de 2026, 23:46 UTC

News
Correlated Moves

Entegris Inc. announced board changes, with Bertrand Loy retiring in 2026. Shares are higher in after-market hours, reflecting a broader Nasdaq 100 increase.

29 de jul. de 2026, 23:41 UTC

News

Claros Mortgage Trust reported a second-quarter net loss of $255.4 million, contributing to a decline in after-market trading. Shares are lower.

29 de jul. de 2026, 23:41 UTC

News

ImmunityBio receives UAE marketing authorization for ANKTIVA®, expanding its reach to 34 countries. Shares are trading higher in after-market hours following the announcement.

29 de jul. de 2026, 23:41 UTC

Social Media
News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

29 de jul. de 2026, 23:41 UTC

News

Churchill Downs shares fell after reporting Q2 adjusted EPS of $3.45, slightly missing estimates, and announcing plans to explore property sales.

29 de jul. de 2026, 23:41 UTC

Social Media
News

Meta Platforms reported second-quarter earnings below expectations, with net income declining to $15.85 billion. Shares fell sharply in after-market trading amid rising costs.

29 de jul. de 2026, 23:41 UTC

Social Media
News

Qualcomm Inc shares fell in after-market trading following weaker-than-expected guidance and a profit decline in its third-quarter fiscal 2026 results.

29 de jul. de 2026, 23:41 UTC

Social Media
News

Modine Manufacturing reported first-quarter net income of $73.9 million, but shares declined in after-market trading following mixed results and revenue that missed estimates.

29 de jul. de 2026, 23:36 UTC

News

Antero Resources shares are lower in after-market trading following a second-quarter earnings report that included an adjusted EPS miss and mixed operational results.

29 de jul. de 2026, 23:36 UTC

News

Peabody Energy announced a quarterly dividend of $0.075 per share after reporting $1 billion in revenue, despite a net loss of $90.6 million. Shares rose in after-market trading.

29 de jul. de 2026, 23:32 UTC

News

Invitation Homes reported strong Q2 results, with net income rising to $218.2 million. Shares are trading higher in after-market hours following the earnings report.

29 de jul. de 2026, 23:32 UTC

News

AXT Inc secures an $87 million supply agreement with Lumentum for indium phosphide wafers, boosting its strategic position in the semiconductor market during after-market hours.

29 de jul. de 2026, 23:31 UTC

News

Saia Inc shares are higher in after-market trading as the company prepares to report earnings. It exceeded revenue expectations with $806.2 million last session.

29 de jul. de 2026, 23:31 UTC

News

DMC Global Inc reported second-quarter sales of $157 million, exceeding estimates. Shares are trading higher in after-market hours following the results.

29 de jul. de 2026, 23:31 UTC

Social Media
News

Lam Research Corp reported strong second-quarter earnings, with adjusted EPS of $1.82 and optimistic guidance for Q3, driving shares higher in after-market trading.

29 de jul. de 2026, 23:31 UTC

News

iShares 7-10 Year Treasury Bond ETF trades lower in after-hours, reflecting market caution amid geopolitical tensions and concerns about rising interest rates and inflation.

29 de jul. de 2026, 23:31 UTC

News

Vanguard Total Bond Market ETF declines in after-market trading amid rising geopolitical tensions and concerns over inflation and interest rates affecting market sentiment.

29 de jul. de 2026, 23:31 UTC

News

RenaissanceRe Holdings increased its share buyback program to $750 million and declared a quarterly dividend of $0.41, driving shares higher in after-market trading.

29 de jul. de 2026, 23:26 UTC

News

Ford Motor Co reported adjusted earnings of $0.42 per share, raising its 2026 guidance and prompting shares to rise in after-market trading.

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

30.55% parte superior

Previsão para 12 meses

Média 14.87 USD  30.55%

Máximo 17 USD

Mínimo 13.6 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

1

Comprar

2

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat